Oruka Therapeutics, Inc. (ORKA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$88.21M

Year ended 2025-12-31

-$100.92M

Trailing 12 months to 2026-06-30

2010-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$88.21M	n/a	2026-03-12, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31	-$5.01M	n/m	2024-02-01, From 2023-01-01
2022-12-31	-$10.91M	n/m	2024-02-01, From 2022-01-01
2021-12-31	-$18.76M	n/m	2023-02-24, From 2021-01-01
2020-12-31	-$7.72M	n/m	2022-03-14, From 2020-01-01
2019-12-31	-$4.80M	n/m	2021-03-18, From 2019-01-01
2018-12-31	-$8.24M	n/m	2020-02-18, From 2018-01-01
2017-12-31	-$17.47M	n/m	2019-02-27, From 2017-01-01
2016-12-31	-$14.99M	n/m	2018-03-22, From 2016-01-01
2015-12-31	-$10.53M	n/m	2017-03-21, From 2015-01-01
2014-12-31	-$9.41M	n/m	2016-03-17, From 2014-01-01
2013-12-31	-$5.29M	n/m	2014-03-20, From 2013-01-01
2012-12-31	-$4.08M	n/m	2014-03-20, From 2012-01-01
2011-12-31	-$6.96M	n/m	2013-03-21, From 2011-01-01
2010-12-31	-$8.32M	n/a	2012-03-27, From 2010-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Oruka Therapeutics, Inc. (ORKA)	2025-12-31	-$88.21M	n/a
Vanda Pharmaceuticals Inc. (VNDA)	2025-12-31	-$109.44M	n/m
Theravance Biopharma, Inc. (TBPH)	2025-12-31	$238.54M	n/m
Rhythm Pharmaceuticals, Inc. (RYTM)	2025-12-31	-$115.67M	n/m
MapLight Therapeutics, Inc. (MPLT)	2025-12-31	-$138.14M	n/m
Enliven Therapeutics, Inc. (ELVN)	2025-12-31	-$70.30M	n/m
Ardelyx, Inc. (ARDX)	2025-12-31	-$42.48M	n/m
Rapport Therapeutics, Inc. (RAPP)	2025-12-31	-$87.47M	n/m
Rigel Pharmaceuticals Inc (RIGL)	2025-12-31	$75.66M	+140.4%

Compare ORKA, VNDA, TBPH, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗